Sign up for the premium plan and unlock all options
After purchasing the premium plan, you will unlock all information about drug prices and their availability.
Search
Listing 472401 - 472420 out of 476480 entries
| Country | ATC | Drug name | Drug form, strength, package | Price level | Price in € | Price in local currency | Therapeutic areas | Manufacturer / Importer |
|---|---|---|---|---|---|---|---|---|
| USA | (L01FX08) elotuzumab | EMPLICITI 300MG INJ | 1 | Ex-factory price without vat |
$0-0 |
$0-0 |
Multiple Myeloma | Bristol-MyersSquibbCompany |
| USA | (L01FX08) elotuzumab | EMPLICITI 400MG INJ | 1 | Ex-factory price without vat |
$0-0 |
$0-0 |
Multiple Myeloma | Bristol-MyersSquibbCompany |
| USA | (L01FX08) elotuzumab | EMPLICITI 400MG INJ | 1 | Ex-factory price without vat |
$0-0 |
$0-0 |
Multiple Myeloma | Bristol-MyersSquibbCompany |
| USA | (L01FX09) mogamulizumab | POTELIGEO 4MG/ML INJ,SOLN | 1X5ML | Ex-factory price without vat |
$0-0 |
$0-0 |
Sezary Syndrome;Mycosis Fungoides | KyowaKirin,Inc. |
| USA | (L01FX09) mogamulizumab | POTELIGEO 4MG/ML INJ,SOLN | 1X5ML | Ex-factory price without vat |
$0-0 |
$0-0 |
Sezary Syndrome;Mycosis Fungoides | KyowaKirin,Inc. |
| USA | (L01FX12) tafasitamab | MONJUVI 200MG INJ,LYPHL | 1 | Ex-factory price without vat |
$0-0 |
$0-0 |
n/a | IncyteCorporation |
| USA | (L01FX13) enfortumab vedotin | PADCEV 20MG/VIAL | 1 | Ex-factory price without vat |
$0-0 |
$0-0 |
Carcinoma, Transitional Cell;Urologic Neoplasms | SeagenInc. |
| USA | (L01FX13) enfortumab vedotin | PADCEV 20MG/VIAL | 1 | Ex-factory price without vat |
$0-0 |
$0-0 |
Carcinoma, Transitional Cell;Urologic Neoplasms | SeagenInc. |
| USA | (L01FX13) enfortumab vedotin | PADCEV 30MG/VIAL | 1 | Ex-factory price without vat |
$0-0 |
$0-0 |
Carcinoma, Transitional Cell;Urologic Neoplasms | SeagenInc. |
| USA | (L01FX13) enfortumab vedotin | PADCEV 30MG/VIAL | 1 | Ex-factory price without vat |
$0-0 |
$0-0 |
Carcinoma, Transitional Cell;Urologic Neoplasms | SeagenInc. |
| USA | (L01FX14) polatuzumab vedotin | POLIVY 140MG/VIAL INJ,LYPHL | 1 | Ex-factory price without vat |
$0-0 |
$0-0 |
Lymphoma, B-Cell | GenentechUSA,Inc. |
| USA | (L01FX14) polatuzumab vedotin | POLIVY 140MG/VIAL INJ,LYPHL | 1 | Ex-factory price without vat |
$0-0 |
$0-0 |
Lymphoma, B-Cell | GenentechUSA,Inc. |
| USA | (L01FX14) polatuzumab vedotin | POLIVY 30MG/VIAL INJ,LYPHL | 1 | Ex-factory price without vat |
$0-0 |
$0-0 |
Lymphoma, B-Cell | GenentechUSA,Inc. |
| USA | (L01FX14) polatuzumab vedotin | POLIVY 30MG/VIAL INJ,LYPHL | 1 | Ex-factory price without vat |
$0-0 |
$0-0 |
Lymphoma, B-Cell | GenentechUSA,Inc. |
| USA | (L01FX18) amivantamab | RYBREVANT 350MG | 7ML | Ex-factory price without vat |
$0-0 |
$0-0 |
Carcinoma, Non-Small-Cell Lung | J&JHealthCareSystemsonbehalfofJanssenBiotechInc. |
| USA | (L01FX18) amivantamab | RYBREVANT 350MG | 7ML | Ex-factory price without vat |
$0-0 |
$0-0 |
Carcinoma, Non-Small-Cell Lung | J&JHealthCareSystemsonbehalfofJanssenBiotechInc. |
| USA | (L01FX24) teclistamab | TECVAYLI 10MG/ML INJ,SOLN,3ML | 3ML | Ex-factory price without vat |
$0-0 |
$0-0 |
Multiple Myeloma | J&JHealthCareSystemsonbehalfofJanssenBiotechInc. |
| USA | (L01FX24) teclistamab | TECVAYLI 10MG/ML INJ,SOLN,3ML | 3ML | Ex-factory price without vat |
$0-0 |
$0-0 |
Multiple Myeloma | J&JHealthCareSystemsonbehalfofJanssenBiotechInc. |
| USA | (L01FX24) teclistamab | TECVAYLI 90MG/ML INJ,SOLN,1.7ML | 1.7ML | Ex-factory price without vat |
$0-0 |
$0-0 |
Multiple Myeloma | J&JHealthCareSystemsonbehalfofJanssenBiotechInc. |
| USA | (L01FX24) teclistamab | TECVAYLI 90MG/ML INJ,SOLN,1.7ML | 1.7ML | Ex-factory price without vat |
$0-0 |
$0-0 |
Multiple Myeloma | J&JHealthCareSystemsonbehalfofJanssenBiotechInc. |
Pages
